Drugs / RUXOPRUBART
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05642546 | Aug 2020 → Jun 2022 | — | NovelMed Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05647811 | May 2027 → Aug 2029 expected | complement 3 glomerulopathy | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06454110 | Feb 2028 → Dec 2030 expected | IgA glomerulonephritis | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05684159 | Nov 2027 → Apr 2030 expected | atypical hemolytic-uremic syndrome | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05646563 | Jan 2027 → Jul 2029 expected | paroxysmal nocturnal hemoglobinuria | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06226662 | Jun 2026 → Oct 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05731050 | Jun 2026 → Sep 2027 expected | paroxysmal nocturnal hemoglobinuria | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06887738 | Jun 2026 → Nov 2027 expected | dermatomyositis | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05646524 | Apr 2026 → Aug 2027 expected | paroxysmal nocturnal hemoglobinuria | NovelMed Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUXOPRUBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068459 ↗ |
| Known as | NM8074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05646563 ↗ |
| Action | Inhibit | “blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases” NCT05642546 ↗ |
| Modality | Monoclonal antibody | “NM8074 is a novel, recombinant, humanized monoclonal antibody.” NCT05642546 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT05642546 ↗ |